Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | MAOA | P21397 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6569882 | 0.90 | CD274 (0.77) | TSHRCD274ALDH1A1HTR1AMAOA | |
| SCHEMBL4488493 | 0.87 | CD274 (0.77) | TSHRCD274ALDH1A1HTR1AMAOA | |
| SCHEMBL2493968 | 0.87 | ALDH1A1 (0.71) | TSHRCD274ALDH1A1HTR1AMAOA | |
| SCHEMBL28212521 | 0.86 | CD274 (0.71) | TSHRCD274ALDH1A1HTR1AMAOA | |
| SCHEMBL2615239 | 0.86 | CD274 (0.92) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL3543817 | 0.86 | CD274 (0.92) | TSHRCD274ALDH1A1HTR1AMAOA | |
| SCHEMBL280240 | 0.86 | MEN1 (0.76) | TSHRCD274ALDH1A1HTR1AMAOA | |
| Moclobemide SCHEMBL3408310 | 0.86 | CD274 (1.00) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL2615238 | 0.86 | CD274 (0.92) | CD274ALDH1A1HTR1AMAOAMAOB | |
| Moclobemide SCHEMBL49708 | 0.86 | CD274 (1.00) | CD274ALDH1A1HTR1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032197-A1 | Methods and compositions for using moclobemide | VELA PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2000006140-A2 | USE OF MOCLOBEMIDE FOR TREATING CERTAIN PHSYCHIATRIC AND MEDICAL DISORDERS | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2000006139-A2 | USE OF MOCLOBEMIDE AND METABOLITES FOR TREATING AND PREVENTING SUBSTANCE ABUSE | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2000006138-A2 | USE OF MOCLOBEMIDE FOR TREATING PAIN AND OTHER DISEASES | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-4210754-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1980-07-01 | — | — | US | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| US-20020032197-A1 | Methods and compositions for using moclobemide | VELA PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2000006140-A2 | USE OF MOCLOBEMIDE FOR TREATING CERTAIN PHSYCHIATRIC AND MEDICAL DISORDERS | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006139-A2 | USE OF MOCLOBEMIDE AND METABOLITES FOR TREATING AND PREVENTING SUBSTANCE ABUSE | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| US-4210754-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032197-A1 | Methods and compositions for using moclobemide | FKBP5, FKBP1B, FKBP3 | TSHR 1438/4885CD274 2615/4885ALDH1A1 3001/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | TSHR 898/4885CD274 4437/4885ALDH1A1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.